Log in

NASDAQ:AMRS - Amyris Stock Price, Forecast & News

$2.28
+0.09 (+4.11 %)
(As of 03/29/2020 05:54 AM ET)
Today's Range
$2.03
Now: $2.28
$2.43
50-Day Range
$1.57
MA: $2.99
$3.85
52-Week Range
$1.40
Now: $2.28
$5.75
Volume2.07 million shs
Average Volume3.05 million shs
Market Capitalization$373.56 million
P/E RatioN/A
Dividend YieldN/A
Beta0.11
Amyris, Inc., an integrated renewable products company, delivers alternatives to petroleum, plant, and animal-based products across a range of consumer and industry segments worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules, specialty ingredients, and consumer products. The company delivers its No Compromise products and services in markets, such as specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Read More
Amyris logo

Industry, Sector and Symbol

Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
Current SymbolNASDAQ:AMRS
CUSIP03236M10
Phone510-450-0761

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$152.56 million
Book Value($2.17) per share

Profitability

Net Income$-242,770,000.00
Net Margins-155.99%

Miscellaneous

Employees414
Market Cap$373.56 million
Next Earnings Date10/5/2020 (Estimated)
OptionableOptionable

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.


Amyris (NASDAQ:AMRS) Frequently Asked Questions

How has Amyris' stock been impacted by COVID-19 (Coronavirus)?

Amyris' stock was trading at $2.96 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AMRS stock has decreased by 23.0% and is now trading at $2.28. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amyris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amyris.

When is Amyris' next earnings date?

Amyris is scheduled to release its next quarterly earnings announcement on Monday, October 5th 2020. View our earnings forecast for Amyris.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) released its quarterly earnings results on Thursday, March, 12th. The biotechnology company reported ($0.70) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.28) by $0.42. The biotechnology company earned $40.54 million during the quarter, compared to analyst estimates of $47 million. View Amyris' earnings history.

When did Amyris' stock split? How did Amyris' stock split work?

Amyris's stock reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for AMRS?

2 Wall Street analysts have issued 12 month price targets for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' share price to reach $9.50 in the next year. This suggests a possible upside of 316.7% from the stock's current price. View analysts' price targets for Amyris.

Has Amyris been receiving favorable news coverage?

Press coverage about AMRS stock has been trending somewhat positive this week, according to InfoTrie. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Amyris earned a coverage optimism score of 1.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutAmyris.

Who are some of Amyris' key competitors?

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Novavax (NVAX), Canopy Growth (CGC), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Intel (INTC), MEI Pharma (MEIP), General Electric (GE) and Amarin (AMRN).

Who are Amyris' key executives?

Amyris' management team includes the following people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 53)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 55)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 55)
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 52)
  • Dr. Joel R. Cherry, Pres of R&D (Age 58)

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (8.01%), Pinnacle Associates Ltd. (1.29%), State Street Corp (0.83%), Geode Capital Management LLC (0.65%), Essex Investment Management Co. LLC (0.42%) and Goldman Sachs Group Inc. (0.29%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View institutional ownership trends for Amyris.

Which institutional investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC, Goldman Sachs Group Inc., Principal Financial Group Inc., Alliancebernstein L.P., Bank of America Corp DE, and Rice Hall James & Associates LLC. Company insiders that have sold Amyris company stock in the last year include John Melo, and Patrick Y Yang. View insider buying and selling activity for Amyris.

Which institutional investors are buying Amyris stock?

AMRS stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Pinnacle Associates Ltd., Essex Investment Management Co. LLC, State Street Corp, Geode Capital Management LLC, Spark Investment Management LLC, Virtus ETF Advisers LLC, and Levin Capital Strategies L.P.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Frank Kung, Kathleen Valiasek, L John Doerr, and Patrick Y Yang. View insider buying and selling activity for Amyris.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $2.28.

How big of a company is Amyris?

Amyris has a market capitalization of $373.56 million and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 414 workers across the globe. View additional information about Amyris.

What is Amyris' official website?

The official website for Amyris is http://amyris.com/.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]


MarketBeat Community Rating for Amyris (NASDAQ AMRS)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  309 (Vote Outperform)
Underperform Votes:  500 (Vote Underperform)
Total Votes:  809
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel